Market Publishers is extremely happy to announce a great discount opportunity on behalf of La Merie Publishing, our Germany-based research partner.
From now all Market Publishers’ customers can become owners of a bundle of market research studies prepared by our partner at a discounted price.
The studies cover:
- Antibody-Drug Conjugates
- Biosimilar and Biosuperior Therapeutic Antibodies
- T-Cell Redirecting Bispecific Antibodies
- Bispecific Antibodies for Cancer, Inflammatory and Other Diseases
Please, find prices for the bundle below:
| License |
Price in EUR (€) |
Price in USD ($) |
| Single User |
3,100 |
3,500 |
| Site License |
6,200 |
7,000 |
| Global License |
9,300 |
10,500 |
By getting simultaneously all four reports mentioned above you will be given a 50% discount on all license types.
Are you interested in this offer? Do not hesitate any more, send us an email.
Publications found:
4
Sort by:
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
US$ 476.00
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory Other Diseases This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory Other Diseases evaluates the competitive ... as: T-Cell or NK cell redirecting bispecific cancer antibodies Bispecific immuno-oncology antibodies Bispecific tumor antigens targeted cancer antibodies Bispecific antibodies for inflammatory autoimmune diseases Bispecific antibodies for cardiometabolic, infectious, neurologic ...
June 2016
180 pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update
US$ 1,184.00
... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...
May 2016
462 pages
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
US$ 2,141.00
... same number of ADC programs are in preclinical R&D. Download Samples Pages: Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis For the first ... entitled „Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis“ is based on the analysis of more than 90 companies, more than 100 ADC drug profiles ...
November 2015
470 pages
